Candel Therapeutics, Inc.
NASDAQ:CADL
Overview | Financials
Company Name | Candel Therapeutics, Inc. |
Symbol | CADL |
Currency | USD |
Price | 8.87 |
Market Cap | 394,497,685 |
Dividend Yield | 0% |
52-week-range | 1.16 - 14.6 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D. |
Website | https://www.candeltx.com |
An error occurred while fetching data.
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD